{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:14:56Z","timestamp":1761750896850,"version":"build-2065373602"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yangzhou Science and Technology Commission","award":["YZ2024120"],"award-info":[{"award-number":["YZ2024120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17567-0","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:12:37Z","timestamp":1761750757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive analysis of coagulation-associated gene signature in bladder cancer diagnosis, prognosis, and immunotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Guicao","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengqi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianchi","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"17567_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"17567_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"17567_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur. Urol. 81, 75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010 (2022).","journal-title":"Eur. Urol."},{"key":"17567_CR4","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. & van der Heijden, M. The bladder cancer immune micro-environment in the context of response to immune checkpoint Inhibition. Front. Immunol. 14, 1235884. https:\/\/doi.org\/10.3389\/fimmu.2023.1235884 (2023).","journal-title":"Front. Immunol."},{"key":"17567_CR5","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea, L. P., Mendez-Marti, S., Kim, D. & Aragon-Ching, J. B. Role of immunotherapy in bladder cancer. Cancer Treat. Res. Commun. 26, 100296. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"17567_CR6","doi-asserted-by":"publisher","first-page":"2045696","DOI":"10.1080\/2162402X.2022.2045696","volume":"11","author":"A Galmiche","year":"2022","unstructured":"Galmiche, A., Saidak, Z. & Ghiringhelli, F. Targeting coagulation to unlock antitumor immunity? Oncoimmunology 11, 2045696. https:\/\/doi.org\/10.1080\/2162402X.2022.2045696 (2022).","journal-title":"Oncoimmunology"},{"key":"17567_CR7","doi-asserted-by":"publisher","unstructured":"Khorana, A. A. et al. Cancer-associated venous thromboembolism. Nat. Rev. Dis. Primers 8. https:\/\/doi.org\/10.1038\/s41572-022-00336-y (2022).","DOI":"10.1038\/s41572-022-00336-y"},{"key":"17567_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder, F. I. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137, 1959\u20131969. https:\/\/doi.org\/10.1182\/blood.2020007338 (2021).","journal-title":"Blood"},{"issue":"Suppl 1","key":"17567_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-2006-939555","volume":"32","author":"W Ruf","year":"2006","unstructured":"Ruf, W. & Mueller, B. M. Thrombin generation and the pathogenesis of cancer. Semin Thromb. Hemost. 32 (Suppl 1), 61\u201368. https:\/\/doi.org\/10.1055\/s-2006-939555 (2006).","journal-title":"Semin Thromb. Hemost."},{"key":"17567_CR10","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/ijc.23240","volume":"122","author":"G Patry","year":"2008","unstructured":"Patry, G. et al. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Int. J. Cancer. 122, 1592\u20131597. https:\/\/doi.org\/10.1002\/ijc.23240 (2008).","journal-title":"Int. J. Cancer"},{"key":"17567_CR11","doi-asserted-by":"publisher","unstructured":"Li, X. et al. Preoperative plasma fibrinogen and D-dimer as prognostic biomarkers for non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer 18, 11\u201319. https:\/\/doi.org\/10.1016\/j.clgc.2019.10.025 (2020).","DOI":"10.1016\/j.clgc.2019.10.025"},{"key":"17567_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/iju.13271","volume":"24","author":"A Alevizopoulos","year":"2017","unstructured":"Alevizopoulos, A. et al. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer. Int. J. Urol. 24, 130\u2013136. https:\/\/doi.org\/10.1111\/iju.13271 (2017).","journal-title":"Int. J. Urol."},{"key":"17567_CR13","doi-asserted-by":"publisher","unstructured":"Johannet, P. et al. Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. J. Transl. Med. 19. https:\/\/doi.org\/10.1186\/s12967-021-02712-w (2021).","DOI":"10.1186\/s12967-021-02712-w"},{"key":"17567_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jcmm.14767","volume":"24","author":"R Cao","year":"2020","unstructured":"Cao, R. et al. An EMT-related gene signature for the prognosis of human bladder cancer. J. Cell. Mol. Med. 24, 605\u2013617. https:\/\/doi.org\/10.1111\/jcmm.14767 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"17567_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1186\/s12885-021-08611-z","volume":"21","author":"J Li","year":"2021","unstructured":"Li, J. et al. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis. BMC Cancer. 21, 858. https:\/\/doi.org\/10.1186\/s12885-021-08611-z (2021).","journal-title":"BMC Cancer"},{"key":"17567_CR16","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572\u20131573. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170 (2010).","journal-title":"Bioinformatics"},{"key":"17567_CR17","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1002\/imt2.231","volume":"3","author":"JM Yang","year":"2024","unstructured":"Yang, J. M. et al. TCellSI: A novel method for T cell state assessment and its applications in immune environment prediction. Imeta 3, e231. https:\/\/doi.org\/10.1002\/imt2.231 (2024).","journal-title":"Imeta"},{"key":"17567_CR18","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher, P., Cox, N. & Huang, R. S. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 9, e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468 (2014).","journal-title":"PLoS One"},{"key":"17567_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"17567_CR20","doi-asserted-by":"publisher","first-page":"27107","DOI":"10.3390\/ijms161126000","volume":"16","author":"M Martinez-Fernandez","year":"2015","unstructured":"Martinez-Fernandez, M. et al. EZH2 in bladder cancer, a promising therapeutic target. Int. J. Mol. Sci. 16, 27107\u201327132. https:\/\/doi.org\/10.3390\/ijms161126000 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"17567_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fphar.2016.00293","volume":"7","author":"L Badimon","year":"2016","unstructured":"Badimon, L., Suades, R., Fuentes, E., Palomo, I. & Padro, T. Role of Platelet-Derived microvesicles as crosstalk mediators in atherothrombosis and future Pharmacology targets: A link between inflammation, atherosclerosis, and thrombosis. Front. Pharmacol. 7, 293. https:\/\/doi.org\/10.3389\/fphar.2016.00293 (2016).","journal-title":"Front. Pharmacol."},{"key":"17567_CR22","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.18632\/aging.205022","volume":"15","author":"Z Gong","year":"2023","unstructured":"Gong, Z. et al. Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer. Aging (Albany NY). 15, 9479\u20139498. https:\/\/doi.org\/10.18632\/aging.205022 (2023).","journal-title":"Aging (Albany NY)"},{"key":"17567_CR23","doi-asserted-by":"publisher","first-page":"1213947","DOI":"10.3389\/fimmu.2023.1213947","volume":"14","author":"C Shen","year":"2023","unstructured":"Shen, C. et al. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. Front. Immunol. 14, 1213947. https:\/\/doi.org\/10.3389\/fimmu.2023.1213947 (2023).","journal-title":"Front. Immunol."},{"key":"17567_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12935-021-01954-4","volume":"21","author":"X Sun","year":"2021","unstructured":"Sun, X. et al. Identification and validation of a hypoxia-related prognostic and immune microenvironment signature in bladder cancer. Cancer Cell. Int. 21, 251. https:\/\/doi.org\/10.1186\/s12935-021-01954-4 (2021).","journal-title":"Cancer Cell. Int."},{"key":"17567_CR25","doi-asserted-by":"publisher","first-page":"19695","DOI":"10.1038\/s41598-020-76688-w","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Identification of immune-related genes as prognostic factors in bladder cancer. Sci. Rep. 10, 19695. https:\/\/doi.org\/10.1038\/s41598-020-76688-w (2020).","journal-title":"Sci. Rep."},{"key":"17567_CR26","doi-asserted-by":"publisher","unstructured":"Moriwaki, M. et al. Relevance of a disintegrin and metalloproteinase domain-containing (ADAM)9 protein expression to bladder cancer malignancy. Biomolecules 12. https:\/\/doi.org\/10.3390\/biom12060791 (2022).","DOI":"10.3390\/biom12060791"},{"key":"17567_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1432-1033.1993.tb19904.x","volume":"211","author":"R Arcone","year":"1993","unstructured":"Arcone, R. et al. Structural characterization of a biologically active human Lipocortin 1 expressed in Escherichia coli. Eur. J. Biochem. 211, 347\u2013355. https:\/\/doi.org\/10.1111\/j.1432-1033.1993.tb19904.x (1993).","journal-title":"Eur. J. Biochem."},{"key":"17567_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/JLB.2MR0717-310R","volume":"103","author":"DA Covino","year":"2018","unstructured":"Covino, D. A., Gauzzi, M. C. & Fantuzzi, L. Understanding the regulation of APOBEC3 expression: current evidence and much to learn. J. Leukoc. Biol. 103, 433\u2013444. https:\/\/doi.org\/10.1002\/JLB.2MR0717-310R (2018).","journal-title":"J. Leukoc. Biol."},{"key":"17567_CR29","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.7150\/jca.46383","volume":"11","author":"W Han","year":"2020","unstructured":"Han, W., Xu, J. & Shen, G. L. Prognostic implication and functional annotations of APOBEC3G expression in patients with melanoma. J. Cancer. 11, 5245\u20135256. https:\/\/doi.org\/10.7150\/jca.46383 (2020).","journal-title":"J. Cancer"},{"key":"17567_CR30","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1002\/cam4.5324","volume":"12","author":"C Olah","year":"2023","unstructured":"Olah, C. et al. Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer. Cancer Med. 12, 5222\u20135232. https:\/\/doi.org\/10.1002\/cam4.5324 (2023).","journal-title":"Cancer Med."},{"key":"17567_CR31","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-05-0259","volume":"11","author":"PJ Wild","year":"2005","unstructured":"Wild, P. J. et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin. Cancer Res. 11, 4415\u20134429. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0259 (2005).","journal-title":"Clin. Cancer Res."},{"key":"17567_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3892\/ol.2023.14175","volume":"27","author":"S Liang","year":"2024","unstructured":"Liang, S., Dang, B., Chen, S. & Mi, H. Prognostic value and immunological role of cathepsin S gene in pan\u2013cancer. Oncol. Lett. 27, 41. https:\/\/doi.org\/10.3892\/ol.2023.14175 (2024).","journal-title":"Oncol. Lett."},{"key":"17567_CR33","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.2174\/0929867331666230824093312","volume":"31","author":"C Mao","year":"2024","unstructured":"Mao, C. & Xu, N. Single-cell sequencing data reveals aggressive CD68-type macrophages and prognostic models in bladder cancer. Curr. Med. Chem. 31, 1523\u20131538. https:\/\/doi.org\/10.2174\/0929867331666230824093312 (2024).","journal-title":"Curr. Med. Chem."},{"key":"17567_CR34","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.2147\/CMAR.S240040","volume":"12","author":"Y Wei","year":"2020","unstructured":"Wei, Y. et al. Upregulation of DUSP14 affects proliferation, invasion and metastasis, potentially via Epithelial-Mesenchymal transition and is associated with poor prognosis in pancreatic cancer. Cancer Manag Res. 12, 2097\u20132108. https:\/\/doi.org\/10.2147\/CMAR.S240040 (2020).","journal-title":"Cancer Manag Res."},{"key":"17567_CR35","doi-asserted-by":"publisher","first-page":"860663","DOI":"10.3389\/fsurg.2022.860663","volume":"9","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. GATA3 predicts the tumor microenvironment phenotypes and molecular subtypes for bladder carcinoma. Front. Surg. 9, 860663. https:\/\/doi.org\/10.3389\/fsurg.2022.860663 (2022).","journal-title":"Front. Surg."},{"key":"17567_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00240-002-0270-5","volume":"30","author":"P Champelovier","year":"2002","unstructured":"Champelovier, P. et al. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis. Urol. Res. 30, 301\u2013309. https:\/\/doi.org\/10.1007\/s00240-002-0270-5 (2002).","journal-title":"Urol. Res."},{"key":"17567_CR37","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.7150\/ijbs.23845","volume":"14","author":"B Yuan","year":"2018","unstructured":"Yuan, B. et al. WDR1 promotes cell growth and migration and contributes to malignant phenotypes of Non-small cell lung cancer through ADF\/cofilin-mediated actin dynamics. Int. J. Biol. Sci. 14, 1067\u20131080. https:\/\/doi.org\/10.7150\/ijbs.23845 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"17567_CR38","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11060-011-0775-2","volume":"107","author":"X Liu","year":"2012","unstructured":"Liu, X. et al. F10 gene hypomethylation, a putative biomarker for glioma prognosis. J. Neurooncol. 107, 479\u2013485. https:\/\/doi.org\/10.1007\/s11060-011-0775-2 (2012).","journal-title":"J. Neurooncol"},{"key":"17567_CR39","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3892\/ol.2017.5749","volume":"13","author":"Y Song","year":"2017","unstructured":"Song, Y. et al. F10, a novel hydatidiform mole-associated gene, inhibits the Paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3. Oncol. Lett. 13, 2563\u20132568. https:\/\/doi.org\/10.3892\/ol.2017.5749 (2017).","journal-title":"Oncol. Lett."},{"key":"17567_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.4049\/jimmunol.1301836","volume":"193","author":"E Maier","year":"2014","unstructured":"Maier, E., Werner, D., Duschl, A., Bohle, B. & Horejs-Hoeck, J. Human Th2 but not Th9 cells release IL-31 in a STAT6\/NF-kappaB-dependent way. J. Immunol. 193, 645\u2013654. https:\/\/doi.org\/10.4049\/jimmunol.1301836 (2014).","journal-title":"J. Immunol."},{"key":"17567_CR41","doi-asserted-by":"publisher","unstructured":"Faraj, S. F. et al. Assessment of tumoral PD-L1 expression and intratumoral CD8\u2009+\u2009T cells in urothelial carcinoma. Urology 85, 703. https:\/\/doi.org\/10.1016\/j.urology.2014.10.020 (2015).","DOI":"10.1016\/j.urology.2014.10.020"},{"key":"17567_CR42","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B. C. et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint Blockade. Nat. Immunol. 20, 326\u2013336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6 (2019).","journal-title":"Nat. Immunol."},{"key":"17567_CR43","doi-asserted-by":"publisher","unstructured":"Beltra, J. C. et al. Developmental relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841. https:\/\/doi.org\/10.1016\/j.immuni.2020.04.014 (2020).","DOI":"10.1016\/j.immuni.2020.04.014"},{"key":"17567_CR44","doi-asserted-by":"publisher","unstructured":"Pichler, A. C. et al. TCR-independent CD137 (4-1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation. Immunity 56, 1631\u20131648. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.007 (2023).","DOI":"10.1016\/j.immuni.2023.06.007"},{"key":"17567_CR45","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.13206","volume":"316","author":"P Laphanuwat","year":"2023","unstructured":"Laphanuwat, P., Gomes, D. C. O. & Akbar, A. N. Senescent T cells: beneficial and detrimental roles. Immunol. Rev. 316, 160\u2013175. https:\/\/doi.org\/10.1111\/imr.13206 (2023).","journal-title":"Immunol. Rev."},{"key":"17567_CR46","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-17-2687","volume":"24","author":"H Fu","year":"2018","unstructured":"Fu, H. et al. Identification and validation of stromal immunotype predict survival and benefit from adjuvant chemotherapy in patients with Muscle-Invasive bladder cancer. Clin. Cancer Res. 24, 3069\u20133078. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2687 (2018).","journal-title":"Clin. Cancer Res."},{"key":"17567_CR47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph, M. & Enting, D. Immune responses in bladder Cancer-Role of immune cell populations, prognostic factors and therapeutic implications. Front. Oncol. 9, 1270. https:\/\/doi.org\/10.3389\/fonc.2019.01270 (2019).","journal-title":"Front. Oncol."},{"key":"17567_CR48","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4111\/icu.20240250","volume":"65","author":"JN Ho","year":"2024","unstructured":"Ho, J. N., Byun, S. S., Kim, D., Ryu, H. & Lee, S. Dasatinib induces apoptosis and autophagy by suppressing the PI3K\/Akt\/mTOR pathway in bladder cancer cells. Investig. Clin. Urol. 65, 593\u2013602. https:\/\/doi.org\/10.4111\/icu.20240250 (2024).","journal-title":"Investig Clin. Urol."},{"key":"17567_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s13104-016-2256-3","volume":"9","author":"S Vallo","year":"2016","unstructured":"Vallo, S. et al. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res. Notes. 9, 454. https:\/\/doi.org\/10.1186\/s13104-016-2256-3 (2016).","journal-title":"BMC Res. Notes"},{"key":"17567_CR50","doi-asserted-by":"publisher","unstructured":"Ko, J. H. et al. The application of Embelin for cancer prevention and therapy. Molecules 23. https:\/\/doi.org\/10.3390\/molecules23030621 (2018).","DOI":"10.3390\/molecules23030621"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17567-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17567-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17567-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:12:37Z","timestamp":1761750757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17567-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17567"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17567-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"24 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37768"}}